If you're looking into growth hormone–releasing peptides, you've probably seen both sermorelin and tesamorelin. Both are GHRH analogs and help your pituitary gland release more growth hormone, but they are not the same. Knowing the differences between sermorelin and tesamorelin can help you and your provider decide which one best fits your needs.
What They Have in Common
Before looking at what sets them apart, it's useful to see what they have in common. Both sermorelin and tesamorelin are synthetic versions of growth hormone–releasing hormone (GHRH). They both bind to GHRH receptors on the pituitary gland and trigger the release of growth hormone. Neither adds growth hormone directly to your body. Both also keep the body's natural feedback system in place, so the pituitary still controls how much growth hormone is made.
In short, both work the same way: they signal the pituitary gland and let it handle the rest.
Key Differences Between Sermorelin and Tesamorelin
The biggest difference between these two peptides is their structure, which affects how they work in the body. Sermorelin is made up of the first 29 amino acids of natural GHRH. Tesamorelin is a modified version of the full 44-amino-acid GHRH molecule, with an added trans-3-hexenoic acid group. This change makes tesamorelin more stable and gives it a longer half-life, so it usually produces a stronger growth hormone response per dose.
Another key difference is in how they are regulated. Tesamorelin is FDA-approved under the brand name Egrifta to reduce excess abdominal fat in HIV-positive patients with lipodystrophy. This means tesamorelin has specific evidence for fat reduction that sermorelin does not. Sermorelin was once FDA-approved but is now mainly used as a compounded peptide.
Comparing Effectiveness
When comparing these GHRH peptides, tesamorelin has stronger clinical data for reducing visceral fat, which is the deeper abdominal fat linked to higher health risks. Clinical trials for Egrifta showed significant reductions in trunk fat compared to placebo. For sermorelin, most evidence for fat reduction comes from clinical observations and smaller studies, but many practitioners report improvements in body composition among their patients.
For broader goals like anti-aging, better sleep, more energy, muscle maintenance, and overall wellness, both peptides are used in clinics and usually get positive feedback from patients. Sermorelin has been used in compounding pharmacies for longer, while tesamorelin's stronger growth hormone boost may help people who need a larger response from their pituitary gland.
Cost and Accessibility Considerations
Cost is an important factor to consider. Tesamorelin, especially the brand-name Egrifta, is usually more expensive than compounded sermorelin. Some people may get insurance coverage for tesamorelin if they meet the FDA-approved criteria, but for other uses, it is usually paid out of pocket. Compounded sermorelin is generally more affordable, which is why it is still widely prescribed for growth hormone optimization.
Side Effect Profiles
Both peptides have similar side effects because they work in the same way. Common side effects include reactions at the injection site, headaches, and sometimes flushing. In clinical trials, some people taking tesamorelin also had joint pain and swelling, but these were usually mild. Sermorelin's side effects are also generally mild and well-tolerated, as explained in our safety article.
Which One Should You Choose?
The best choice depends on your health, goals, and budget. If reducing visceral fat is your main goal and you want a peptide with FDA-backed data for that, tesamorelin is worth talking about with your provider. If you want a well-known, affordable peptide for general growth hormone support, sermorelin is a solid option with many years of clinical use.
At HRT Wellness, our medical team looks at each patient's needs and helps decide which peptide or combination of treatments fits your goals best. Contact us to schedule a consultation and learn more about your options.
References
- Falutz J, et al. Effects of tesamorelin on body composition and metabolic indices in HIV-infected patients. Annals of Internal Medicine. 2007;147(5):291–299.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307–308.
- Stanley TL, et al. Effects of tesamorelin on cardiovascular markers in HIV patients with excess abdominal fat. JAMA. 2014;312(4):380–389.